Format

Send to

Choose Destination
See comment in PubMed Commons below
MAbs. 2011 Nov-Dec;3(6):503-4. doi: 10.4161/mabs.3.6.17611. Epub 2011 Nov 1.

Aggregation, immune complexes and immunogenicity.

Abstract

The development of an immune response to a protein therapeutic may nullify its beneficial activity or result in adverse events. Immunogenicity is, therefore, a major concern for clinicians, regulatory authorities and the biopharmaceutical industry. These concerns are particularly acute for the treatment of chronic diseases, as opposed to cancer, that may require repeated exposure to therapeutic over extended cycles of remission/relapse. There are many parameters that may be contributory to immunogenicity; however, the "bĂȘte noire," for the past decade has been aggregation. ( 1-3).

PMID:
22123066
PMCID:
PMC3242835
DOI:
10.4161/mabs.3.6.17611
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center